Characteristic |
All Patients |
BiV |
MPP |
P (BiV vs.
MPP) |
Sample size, n (%) |
142 (100.0%) |
69 (48.6%) |
73 (51.4%) |
|
Male, n (%) |
96/142 (67.6%) |
48/69 (69.6%) |
48/73 (65.8%) |
0.720 |
Age, yr |
61.2 [52.3, 67.9] |
59.6 [52.1, 67.0] |
62.1 [52.3,
69.4] |
0.251 |
NYHA, n (%) |
|
|
|
0.186 |
I |
0/142 (0.0%) |
0/69 (0.0%) |
0/73 (0.0%) |
|
II |
27/142 (19.0%) |
16/69 (23.2%) |
11/73 (15.1%) |
|
III |
107/142 (75.4%) |
50/69 (72.5%) |
57/73 (78.1%) |
|
IV |
8/142 (5.6%) |
3/69 (4.3%) |
5/73 (6.8%) |
|
Ischemic, n (%) |
47/142 (33.1%) |
21/69 (30.4%) |
26/73 (35.6%) |
0.593 |
Hypertension, n (%) |
81/142 (57.0%) |
34/69 (49.3%) |
47/73 (64.4%) |
0.090 |
Diabetes, n (%) |
74/142 (52.1%) |
39/69 (56.5%) |
35/73 (47.9%) |
0.319 |
QRS duration, ms |
158.0 [150.0, 170.0] |
158.0 [150.0, 170.0] |
160.0 [150.0, 172.3] |
0.434 |
LVESV, mL |
135.0 [102.0, 200.0] |
140.0 [102.0, 191.0] |
130.0
[103.0, 206.0] |
1.000 |
LVEDV, mL |
185.5 [148.0, 265.0] |
185.0 [163.8, 250.0] |
188.0
[145.0, 274.0] |
0.920 |
LVSV, mL |
50.0 [39.0, 61.0] |
50.0 [40.0, 60.3] |
49.0 [37.3,
63.5] |
0.612 |
LVEF, % |
25.8 [21.2, 33.3] |
25.7 [21.7, 32.5] |
26.0 [21.1,
33.6] |
0.922 |